CDKN2A and cervical cancer: Similar to earlier studies focused on the application of the HPV DNA and p16INK4A immunocytochemical co‐test for triaging women with higher risks of cervical cancer,11, 12, 13, 14, 15 we verified that the combination of p16INK4A FCM and HPV DNA tests could be superior to the traditional HPV DNA and Pap co‐test in screening of HSILs with regard to their respective diagnostic parameters, namely, sensitivity (89.5 vs.